<DOC>
	<DOCNO>NCT00442650</DOCNO>
	<brief_summary>Multicentre , open label , phase III study . Subjects moderate severe psoriasis give efalizumab subcutaneously per week 12-week treatment period . Assessments involve physical examination , disease activity assessment , clinical laboratory test ( haematology , blood chemistry standard urinalysis ) , evaluation Psoriasis Area Severity Index ( PASI ) , Physician 's Global Assessment ( PGA ) , Patient 's Global Psoriasis Assessment ( PGPA ) , SF-36 Health Survey psoriatic body surface area ( BSA ) . The 12-week treatment period follow 12-week follow-up ( FU ) period , antipsoriatic medication allow . The assessment also perform 12-week FU period .</brief_summary>
	<brief_title>Efalizumab Treatment Patients With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Signed informed consent 2 . Plaque psoriasis cover ³10 % total BSA 3 . Diagnosis plaque psoriasis least 6 month 4 . A minimum PASI score 12.0 screen 5 . In opinion investigator , candidate systemic therapy psoriasis 6 . Body weight £120 kg 7 . 18 75 year old 8 . For woman childbearing potential men whose partner become pregnant , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study ( include FU period ) . 9 . Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study 10 . Willingness enter Study 1 . Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis 2 . History severe allergic anaphylactic reaction humanise monoclonal antibody fusion protein contain Ig Fc region 3 . Clinically significant psoriasis flare screen time enrollment would necessitate immediate relief patient 4 . History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection 5 . History opportunistic infection ( e.g. , systemic fungal infection , parasite ) 6 . Seropositivity human immunodeficiency virus ( HIV ) Patients undergo mandatory test screening . Patients positive HIV exclude . 7 . Pregnancy lactation 8 . WBC count &lt; 4000/mL &gt; 14,000/mL 9 . Patients history clinically significant thrombocytopenia , bleed disorder platelet count &lt; 100,000/mL 10 . Seropositivity hepatitis B C virus Patients undergo test screening . Patients positive hepatitis B antigen hepatitis C antibody exclude . 11 . Hepatic enzymes ³3 time upper limit normal 12 . History active tuberculosis ( TB ) currently undergo treatment TB Chest Xray within 3 month Day 0 require patient . Patients positive chest Xray consistent TB infection exclude . 13 . Presence malignancy within past 5 year , include lymphoproliferative disorder Patients history fully resolve basal cell squamous cell skin cancer may enrol even less 5 year . 14 . Previous treatment efalizumab ( antiCD11a ) 15 . Diagnosis hepatic cirrhosis , regardless cause severity 16 . Serum creatinine ³2 time upper limit normal 17 . Hospital admission cardiac disease , stroke , pulmonary disease within last year 18 . History substance abuse ( e.g . narcotic , alcohol ) within last 5 year 19 . Any medical condition , judgment investigator , would jeopardize patient 's safety follow exposure study drug Note : Restrictions and/or direction apply follow treatment specified time period prior initial study drug administration study : 20 . Systemic therapy psoriasis within 28 day prior Study Day 0 21 . Systemic immunosuppressive drug indication within 28 day prior Study Day 0 22 . Topical therapy psoriasis within 14 day prior Study Day 0 23 . Live kill virus bacteria vaccine within 14 day prior Study Day 0 24 . Other vaccine allergy desensitization within 14 day prior study Day 0 25 . Other experimental drug treatment within 28 day five half life , whichever longer , prior Day 0 26 . Use b Blockers , ACE inhibitor , interferon , quinidine , antimalarial drug , lithium ( clinically indicate , medication allow dosage hold constant Day 28 throughout study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>